338 related articles for article (PubMed ID: 18793400)
1. Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study.
Thom KA; Schweizer ML; Osih RB; McGregor JC; Furuno JP; Perencevich EN; Harris AD
BMC Infect Dis; 2008 Sep; 8():116. PubMed ID: 18793400
[TBL] [Abstract][Full Text] [Related]
2. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
3. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
4. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
[TBL] [Abstract][Full Text] [Related]
5. [Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].
Perianes-Díaz ME; Novo-Veleiro I; Solís-Díaz K; Prolo-Acosta A; García-García I; Alonso-Claudio G
Med Clin (Barc); 2014 May; 142(9):381-6. PubMed ID: 23735867
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
7. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?
Lodise TP; Zhao Q; Fahrbach K; Gillard PJ; Martin A
BMC Infect Dis; 2018 Dec; 18(1):625. PubMed ID: 30518337
[TBL] [Abstract][Full Text] [Related]
9. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.
Cheng WL; Hsueh PR; Lee CC; Li CW; Li MJ; Chang CM; Lee NY; Ko WC
J Microbiol Immunol Infect; 2016 Apr; 49(2):208-15. PubMed ID: 25070279
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.
Frakking FN; Rottier WC; Dorigo-Zetsma JW; van Hattem JM; van Hees BC; Kluytmans JA; Lutgens SP; Prins JM; Thijsen SF; Verbon A; Vlaminckx BJ; Cohen Stuart JW; Leverstein-van Hall MA; Bonten MJ
Antimicrob Agents Chemother; 2013 Jul; 57(7):3092-9. PubMed ID: 23612198
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.
Ku NS; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Kim SB; Kim HW; Jeong SJ; Han SH; Kim CO; Song YG; Kim JM; Choi JY
Arch Gerontol Geriatr; 2014; 58(1):105-9. PubMed ID: 23988261
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of C-reactive protein for evaluating clinical outcomes in cirrhotic patients with bacteremia.
Ha YE; Kang CI; Joo EJ; Joung MK; Chung DR; Peck KR; Lee NY; Song JH
Korean J Intern Med; 2011 Jun; 26(2):195-200. PubMed ID: 21716910
[TBL] [Abstract][Full Text] [Related]
15. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study.
Peralta G; Lamelo M; Alvarez-García P; Velasco M; Delgado A; Horcajada JP; Montero M; Roiz MP; Fariñas MC; Alonso J; Martínez LM; Gutiérrez-Macías A; Alava JA; Rodríguez A; Fleites A; Navarro V; Sirvent E; Capdevila JA;
BMC Infect Dis; 2012 Oct; 12():245. PubMed ID: 23038999
[TBL] [Abstract][Full Text] [Related]
16. Does inappropriate initial antibiotic therapy affect in-hospital mortality of patients in the emergency department with
Chen FC; Ho YN; Cheng HH; Wu CH; Change MW; Su CM
Int J Immunopathol Pharmacol; 2020; 34():2058738420942375. PubMed ID: 32698638
[TBL] [Abstract][Full Text] [Related]
17. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
[TBL] [Abstract][Full Text] [Related]
19. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
[TBL] [Abstract][Full Text] [Related]
20. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
